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Background: While breast cancer (BC) is the major cause of death among women worldwide, there is no
guarantee of better patient survival because many of these patients develop primarily metastases, despite efforts
to detect it in its early stages. Bone metastasis is a common complication that occurs in 65-80 % of patients with
disseminated disease, but the molecular basis underlying dormancy, dissemination and establishment of
metastasis is not understood. Our objective has been to evaluate simultaneously osteoprotegerin (OPG), receptor
activator of nuclear factor kappa B ligand (RANKL), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL),
stromal cell-derived factor-1 (SDF-1), and their receptors (R) in 2 human BC cell lines, MDA-MB-231 and MCF-7.
Methods: OPG, RANKL, TRAIL and SDF-1 expression and release, in addition to the expression of their receptors
has been investigated using immunofluorescence, immunocytochemistry and ELISA analyses.
Results: MCF-7 cells released higher levels of OPG in conditioned media (CM) than MDA-MB-231 cells; 100 % of
both types of cell expressed OPG, RANKL, TRAIL and SDF-1. Moreover, 100 % in both lines expressed membrane
RANKL and RANK, whereas only 50 % expressed CXCR4. Furthermore, 100 % expressed TRAIL-R1 and R4, 30-50 %
TRAIL-R2, and 40-55 % TRAIL-R3.
Conclusions: MCF-7 and MDA-MB-231 cells not only released OPG, but expressed RANKL, TRAIL and SDF-1. The
majority of the cells also expressed RANK, CXCR4 and TRAIL-R. Since these ligands and their receptors are
implicated in the regulation of proliferation, survival, migration and future bone metastasis during breast tumor
progression, assessment of these molecules in tumor biopsies of BC patients could be useful in identifying
patients with more aggressive tumors that are also at risk of bone metastasis, which may thus improve the
available options for therapeutic intervention.
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Breast cancer (BC) remains the most common cancer
among women in both the United States and worldwide
[1-4]. Many individuals with BC develop metastases to
secondary organs, e.g. bone marrow (BM) and bone [1-
3,5].
The development and spread of tumors are due to the
ability of malignant cells to avoid detection and removal
by the immune system, grow in non-native sites and
avoid programmed or induced cell death [6]. Indeed,
70 % of patients with advanced BC develop metastases
in BM and bone (osteolytic lesions) within one year after
diagnosis of the primary tumor [2,7]. However, the fac-
tors favoring BC growth in both the primary tumor and
metastatic sites are unclear, making the mechanisms
involved by which primary tumor cells metastasize to
secondary organs a major clinical challenge.
Focusing on bone metastasis, there is a vicious cycle
between bone resorption and tumor proliferation in
which osteoprotegerin (OPG), receptor (R) activator of
nuclear factor kappa B (RANK), RANK ligand (RANKL)
and tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) play a pivotal role [8-10].
OPG, a member of the TNF-R superfamily, binds
RANKL, blocking its interaction with RANK and
thereby preventing osteoclast differentiation, activation
and survival [7,11].
The BC cell line MDA-MB-231 produces sufficient
OPG to bind TRAIL, which upregulates RANKL expres-
sion [6]. Briefly, OPG secreted by this BC cell line, acting
as a paracrine factor, could affect RANKL production,
enhancing osteolysis and the perpetuation of this vicious
cycle [6]. In human malignancies that metastasize to
bone, dysregulation of the RANK/RANKL/OPG pathway
can increase the RANKL: OPG ratio, which would favor
excessive osteolysis [12-15]. In a mouse model of bone
metastasis, the RANKL protein levels in MDA-MB-231
tumor-bearing bones were significantly higher than in
tumor-free bones [16]. The resulting tumor-induced
osteoclastogenesis and osteolysis were inhibited by re-
combinant OPG in a dose-dependent manner. Inhibition
of RANKL blocked tumor-induced osteolysis and skeletal
tumor progression and improved survival in murine
models of BC bone metastasis [17]. RANK allows cells to
proliferate, migrate and invade other tissues, specifically
BM and bone. Additionally, RANK is expressed in many
different epithelial tissues and epithelial tumor cells, and
in vitro stimulation of human BC cell lines (MDA-
MB-231, MCF-7 and Hs578T) with RANKL results in
concentration-dependent cell migration, which is
blocked by recombinant OPG [7]. Moreover, OPG also
binds to TRAIL and inhibits its pro-apoptotic effect [18].
TRAIL induces apoptosis through the death receptors
DR4/R1 and DR5/R2 that are expressed on the surfaceof target cells [19-22]. In preclinical models, TRAIL has
anticancer activity [23]. Unfortunately, > 50 % of the
tumor cells are resistant to TRAIL. In some cases,
TRAIL resistance is caused by a high and simultaneous
expression of other TRAIL-R-like decoy R (DcR1/R3
and DcR2/R4) and soluble OPG [24]. However, the pres-
ence of decoy R cannot explain the lack of response of
many cancer cells to antibodies specifically targeting
DR4, DR5 or recombinant TRAIL. TRAIL resistance in
BC cells has been associated with constitutive endocyto-
sis of death receptors 4 and 5 (R1 and R2) [24]. Thus, it
is important to develop new strategies to overcome this
type of resistance in tumor cells. Interestingly, some
groups have described the ability of subtoxic concentra-
tions of chemotherapeutic drugs to sensitize tumor cells
resistant to TRAIL [23,25,26]. Also the anticancer effi-
cacy of TRAIL against BC cells is known to be retained
in the bone microenvironment, even in the present of
biologically active OPG at a supraphysiologic concentra-
tion [18].
Finally, SDF-1, a member of the CXC subfamily of che-
mokines that mediates several cellular functions (adhe-
sion, survival, proliferation and migration) via interaction
with CXCR4, is found at high levels in organs to which
BC frequently metastasizes, which include lymph nodes,
lungs, liver and bone [27]. CXCR4 is expressed by fibro-
blasts, endothelial, hematopoietic cells and stromal cells,
in different types of cancer cells, such as BC cells, and in
numerous types of embryonic and adult stem cells (SCs),
which can be chemoattracted by its ligand, SDF-1 [28-
31]. CXCR4 expression in tumor cells of several types of
carcinomas is correlated with a poor prognosis, e.g.
breast and prostate tumors [27,28,32-34]. Furthermore,
CXCR4 overexpression in BC cells is correlated with a
worse prognosis and decreased patient survival, irre-
spective of the status of the estrogen-receptor (ER) [35].
Knockdown of CXCR4 expression using small interfering
RNA in BC cells decreases in vitro cell survival, invasion
and proliferation and abrogates in vivo tumor growth
[28,34,36,37]. In addition SDF-1/CXCR4 in malignant
tumors could provide paracrine signals that promote
malignant progression, i.e. invasion and cell prolifera-
tion that leads to metastasis [28,38]. In contrast, a
high level of SDF-1 expression (in a cytoplasmic-
dominant pattern) in BC cells seems to be a signifi-
cant indicator of a better clinicopathological outcome,
particularly in patients with ER-positive, HER-2-
negative, and lower grade tumors [29]. Moreover, Cor-
coran et al. [39] detected membrane-bound SDF-1 in
MCF-7 and T47D BC cell lines, but not in the MDA-
MB-231 cell line, which could be relevant in the inter-
action with CXCR4-expressing mesenchymal stem cells
[39,40]. They also suggested that SDF-1 might occupy
CXCR4 in BC cells through autocrine binding, possibly
Labovsky et al. Cancer Cell International 2012, 12:29 Page 3 of 13
http://www.cancerci.com/content/12/1/29resulting in these cells losing their efficiency in metasta-
sizing to organs with a high concentration of SDF-1.
They proposed that CXCR4 antagonists might be ideal
for patients who are diagnosed early without lymph
node involvement [41]. This type of therapy could be
prudent in preventing low numbers of BC cells from
entering BM and bone.
A better understanding of the interactions between
complex tumor cells and host cells focusing on the bone
microenvironment, along with a better understanding of
the autocrine and paracrine effects of the factors
secreted from tumor cells and bone matrix may facilitate
the development of effective strategies that inhibit meta-
static disease progression. It is also important to study
the early events involved in BC cell entry into the BM.
Therefore, since these ligands and their receptors are
molecules involved in the proliferation, survival, migration
and possible future BM/bone metastasis of BC cells,
studying their simultaneous in vitro expression in human
BC cell lines, such as the ER-negative MDA-MB-231
(highly invasive and metastatic cells) and ER-positive
MCF-7 (weakly invasive and metastatic cells), offers an ap-
proach to a better understanding of their involvement in
the evolution of BC. Much of the available data about the
expression of these factors and receptors in BC cells is to
some degree contradictory. Hence, it is important to study
the expression and release of these ligands and the expres-
sion of their receptors with time (after 1-4 days) and
under conditions of arrest and post-stimulation with 10 %
fetal bovine serum (FBS) for 48 h.Results
Analysis of the levels of OPG, RANKL, TRAIL and SDF-1 in
conditioned media from MDA-MB-231 and MCF-7 cells by
ELISA
Since increasing the cell concentration of either BC lines
(18x103 or 50x103 cells/cm2) did not change the levels of
OPG, RANKL, TRAIL and SDF-1 under traditional cul-
ture conditions (data not shown), our results represent
only the levels using 18x103 cell/cm2 in both culture
conditions.
The level of OPG in CM of the MDA-MB-231 cells
increased progressively over time, with a maximum at day
4 (D4), whereas in the CM of the MCF-7 cells, the highest
level happened after 48 h (day 2, D2) (Figure 1A). MCF-7
cell line released higher levels of OPG than the MDA-
MB-231 line at D2 (p< 0.05, Bonferroni post hoc test).
Both cell lines expressed different levels of OPG under
conditions of arrest and post-stimulation (Figure 1B).
However, the levels of OPG produced after stimulation
were higher in the MCF-7 cells compared to the MDA-
MB-231 cells (p = 0.0130, unpaired t-test with Welch's
correction).Regardless of the culture conditions and the type of BC
cell line used, the levels of RANKL, TRAIL and SDF-1
were below the ELISA detection limit (< 31.25 pg/ml).
Analysis of the expression of OPG, RANKL and TRAIL in
MDA-MB-231 and MCF-7 cells by immunofluorescence
In vitro traditional culture condition results in both BC
cell lines expressing similar levels of OPG, RANKL and
TRAIL (Figure 2A). MDA-MB-231 and MCF-7 cells dis-
played a decrease in OPG expression at day 2. OPG,
RANKL and TRAIL were expressed in 100 % of the BC
cells. No immunostaining was observed when the MDA-
MB-231 and MCF-7 cells were incubated either without
a primary antibody (Ab) or with an irrelevant Ab as a
negative isotype control. Figure 2B shows only the
results obtained from the two BC cell lines grown until
D4 as representative results.
RANKL and TRAIL were also expressed in 100 % of
the MDA-MB-231 and MCF-7 cells, under conditions of
both arrest and post-stimulation (Figure 3A). Independ-
ently of the cell type used, this expression/cell was
higher post-stimulation. Regarding the production of
OPG its expression/cell was minimal under arrest condi-
tions but increased post stimulation. No immunofluores-
cence was observed when the primary Ab was omitted
or other negative controls were used (Figure 3B).
Evaluation of the expression of membrane RANKL in
MDA-MB-231 and MCF-7 cells by immunocytochemistry
Independently of the culture conditions or the cell con-
centration plated, RANKL was undetectable in the CM
of the MDA-MB-231 and MCF-7 cells. Membrane ex-
pression of RANKL (mRANKL) should be evaluated as
its functions could be assessed not only as soluble fac-
tor but also as a membrane protein via cell-to-cell con-
tact through RANK. Immunocytochemistry analysis of
the MDA-MB-231 and MCF-7 cells showed positive
and similar expression of membrane and cytoplasmatic
RANKL (cRANKL) in 100 % of cells under both cul-
ture conditions. Figure 4A and B show the results from
both BC cell lines grown under traditional culture con-
ditions for 24 h (day 1, D1) and arrest and post-
stimulation culture conditions. Positive expression for
AE1AE3 was used as a positive control. No immunos-
taining was observed in any of the cells when they
were incubated without specific primary Abs or with
other negative control.
Evaluation of the expression of RANK, SDF-1 and
CXCR4 in MDA-MB-231 and MCF-7 cells by
immunocytochemistry
Immunocytochemistry analysis of membrane and cyto-
plasmic RANK (mRANK and cRANK) displayed 100 %
positive expression in MDA-MB-231 and MCF-7 cells
Figure 1 Release of OPG from BC cell lines under two different culture conditions detected by ELISA. (A) Traditional culture conditions.
Conditioned media (CM) from the cell cultures at 24, 48, 72 and 96 h [Days (D): D1-D4] from both BC cell lines were used to evaluate the levels
of OPG by ELISA. The values of OPG are expressed as X pg/ml/ 1x106 cells + standard error (SE). Statistical significance: One-way analysis of
variance (ANOVA) followed by a Bonferroni post hoc test. Asterisks (*) indicate a significant difference (p <0.05) compared to D1 for each cell line.
(B) Arrest and post-stimulation culture conditions. CM obtained under arrest at 48 h and subsequent stimulation with 10 % SBF for 48 h from
both BC cell lines were used to evaluate the levels of OPG by ELISA. The OPG values are expressed as X pg/ml/ 1x106 cells + standard error (SE).
Statistical significance: Unpaired t-test with Welch's correction. Asterisks (*) indicate a significant difference (p = 0.0158, * and p = 0.0056, **)
between OPG production during arrest and after stimulation in the MDA-MB-231 and MCF-7 cell lines.
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the results from the two BC cell lines grown under ar-
rest and post-stimulation culture conditions.
One hundred of BC cells expressed SDF-1 under both
culture conditions. In contrast, 50 % of these cells
showed a weak CXCR4 expression under both culture
conditions. But, there was an increase of expression after
stimulation and on days 1 to 4 under traditional culture
conditions. Figure 5A and B show the results obtained
for BC cells grown under arrest and post-stimulation
culture conditions. No staining was observed in the
negative controls (Figure 5B).
Evaluation of the expression of TRAIL and its receptor in
MDA-MB-231 and MCF-7 cells by immunocytochemistry
Figures 6A and B show the results obtained from the
two BC cell lines grown under arrest and post-
stimulation culture conditions. Immunocytochemistry
staining of MDA-MB-231 and MCF-7 cells exhibited
positive and similar expression patterns of TRAIL-R1
and R4 in 100 % of cells in cultures of both lines
(Figure 6A). However, TRAIL-R2 and TRAIL-R3 were
weakly expressed. TRAIL-R2 expression was stronger in
MDA-MB-231 cells than in MCF-7 cells, with 30 to
50 % of cells showing staining in cultures of both celllines. TRAIL-R3 was expressed with the same intensity
in culture, showing 40 to 55 % positive cells.
Positive expression of AE1AE3 (used as a positive con-
trol) was observed. In cultures where the primary Ab
was omitted or other negative controls were used, negli-
gible staining was observed (Figure 6B).
Discussion
Bone metastasis is a common event in advanced breast
cancer. Once tumors metastasize to bone, they are usu-
ally incurable, with a five-year survival rate of 20 % [42].
MCF-7 and MDA-MB-231 cell lines, extracted from
pleura, are metastatic and belonged to BC patients at an
advanced clinical stage. In addition, Corcoran et al.
found a low invasivity preference of MCF-7 and T47D
cells to BM, but MDA-MB-231 cells are highly meta-
static to lung and BM [39]. Based on these background
findings, the results presented in this work may contrib-
ute to in vitro analysis of the expression and release of
factors involved in the BM/bone metastasis of BC cells,
such as OPG, RANKL, TRAIL, SDF-1 and their
receptors.
OPG and its two ligands, TRAIL and RANKL, are
expressed at different levels in normal breast tissue and
breast tumor tissue [43]. However, it is not fully
Figure 2 Immunofluorescence detection of OPG, RANKL and TRAIL in both BC cell lines grown under Traditional culture conditions. (A)
Immunofluorescence staining for OPG, RANKL and TRAIL was positive in both BC cell lines. D: day; D0: cells at time zero; D1, D2, D3 and D4: cell
lines grown for 24, 48, 72 and 96 h, respectively. The insert shows nuclear DNA stained with DAPI. The scale bar represents 30 μm. (B) Both BC
cell lines were grown until D4 (96 h) and incubated either without a primary Ab and with the followings Abs: a) Cy3-labeled goat anti-mouse
IgG, b) FITC-labeled goat anti-rabbit IgG, c) an irrelevant Ab as a negative isotype control, such as IgG1, d) mouse Igs and e) rabbit Igs. In controls
c and d, the cell lines were stained with a Cy3-labeled goat anti-mouse IgG Ab, and in control e, they were stained using a FITC-labeled goat
anti-rabbit IgG Ab. The insert shows nuclear DNA stained with DAPI. The scale bar represents 30 μm.
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BC, and which types of cells produce them within the
tumor microenvironment. Therefore, OPG could exert
either anti- or pro-tumoral effects in cells based on
whether it binds RANKL or TRAIL, which depends on
the relative concentrations of the two cytokines in BC
tissue during tumor progression [8,11,44,45]. OPG bind-
ing to TRAIL inhibits the apoptosis of some BC cells, in-
creasing their survival. Nevertheless, OPG binding to
RANKL inhibits osteoclastogenesis and in some BC cells,
decreases the ability to migrate, especially to BM/bone,
due to inhibiting the interaction between RANKL andRANK [7,46]. RANKL is abundantly expressed in BM/
bone [7]. Recently, Santini et al. demonstrated that
RANK expression in primary tumors from BC patients is
a predictive marker of both the occurrence of BM/bone
metastasis and of shorter skeletal disease-free survival
[47].
TRAIL acts as an apoptotic factor in osteoclasts and
in BC cells (ER negative) [48,49]. In primary breast
tumor and metastatic sites, TRAIL is released by BC
cells, activated fibroblasts, macrophages, lymphocytes
and post- TNF-α/interferon-α/-γ stimulated mesenchy-
mal stem cells (MSCs) [8,43,45,50].
Figure 3 Expression of OPG, RANKL and TRAIL in both BC cell lines. (A) Immunofluorescence staining for OPG, RANKL and TRAIL in both BC
cell lines grown under arrest and post-stimulation culture conditions. The scale bar represents 50 μm. (B) The MDA-MB-231 and MCF-7 cell lines
were grown under arrest and post-stimulation culture conditions and incubated either without a primary Ab and with the followings Abs: a) Cy3-
labeled goat anti-mouse IgG, b) FITC-labeled goat anti-rabbit IgG, c) an irrelevant Ab as a negative isotype control, such as IgG1, and d) rabbit Igs.
In control c, the cell lines were stained with a Cy3-labeled goat anti-mouse IgG Ab, and in control d, they were stained with a FITC-labeled goat
anti-rabbit IgG Ab. The insert shows nuclear DNA stained with DAPI. The scale bar represents 30 μm.
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tion to BM/bone is not fully understood because of the
low levels of secretion compared to those produced by
MSCs from BM and osteoblasts [44]. Accordingly, we
found that both the MDA-MB-231 and MCF-7 cell lines,
independent from being ER positive or negative,
expressed and released OPG. The OPG levels detected
in the CM from both culture conditions were lower than
the levels found in previous studies from our laboratory
working with the CM of MSCs from the BM of healthy
volunteers and untreated advanced BC patients free of
BM and bone metastases [51,52]. Therefore, we can con-
clude that when BC cells first enter BM/bone, they re-
lease OPG that may be important via binding to TRAIL
secreted by osteoclasts or other cells of the stromal
microenvironment. Moreover, BC cells can play a role in
the distance releasing of OPG or other factors to the cir-
culation, hence exerting its action in BM/bone. Thus,
BC cells may inhibit their own and osteoclasts apoptosis
and further contribute to the spontaneous osteoclasto-
genesis observed by our group in the peripheral blood
and BM of untreated advanced BC patients prior to
bone metastasis [51,52]. However, this last interactioncannot significantly modify the production of osteoclasts
because it is triggered by the hematopoietic microenvir-
onment, especially MSCs and osteoblasts, prior to the
arrival of tumor cells and of the development of bone
metastasis [51,52].
Furthermore, OPG can be regulated by sulfated pro-
teoglycans (PGs), which inhibit the adherence and re-
sorptive activity of osteoclasts [8,53]. The capture of
OPG in the extracellular matrix of BM/bone favors bone
osteolysis, further contributing to bone disorders leading
to the appearance of metastasis. The PG-OPG inter-
action blocks OPG activity via preventing binding to
TRAIL and RANKL as well as decreasing its half-life
[8,53,54]. Therefore, the OPG anti- or pro-tumor activity
in the BM/bone microenvironment is determined by the
relative concentrations of each of its ligands (RANKL,
TRAIL and sulfated PG) [8]. In contrast, recent data
indicated that the role of OPG released by BC cells
injected intratibially into normal mice preserved the in-
tegrity of bone and prevented BC-induced bone destruc-
tion because its principal role is binding RANKL in vivo
[18]. Finally, OPG increases endothelial cell survival and
induces angiogenesis, favoring further development of
Figure 4 Expression of membrane RANKL on BC cell lines under the two different culture conditions. (A) Immunocytochemistry staining
for mRANKL in the MDA-MB-231 cell line under both culture conditions (x 400 magnification). (B) Immunocytochemistry staining for mRANKL in
the MCF-7 cell line under both culture conditions (x 400). Positive controls were performed in both BC cell lines incubated with anti-RANKL
(cytoplasmatic RANKL= cRANKL, evaluated previously) and anti-AE1AE3 (a pan-cytokeratin epithelial marker). No staining was observed in both BC
cell lines incubated with an irrelevant rabbit Ig Ab as a negative isotype control. Nuclei were counterstained with hematoxylin (purple).
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cluding to BM and bone [11].
As stated, BC cells from the MCF-7 and MDA-MB-
231 cell lines released OPG, independent of the culture
conditions used. MCF-7 line released was greater and
faster as a function of time. These results are consistent
with those of other authors who found that the produc-
tion of OPG is higher in ER-positive cells in primary
tumors than in ER-negative cells [43,55]. In addition,
Holen et al. have observed that after culturing the MDA-
MB-231 line for 72 h, the cells produced 768± 64 pg/ml
of OPG [55], which is very similar to the levels we
obtained for this line on the third day (614.20 ± 161 pg/ml,
traditional culture conditions). In contrast, other authors
have detected OPG levels of approximately 1,750 pg/ml in
MDA-MB-436 cells and comparable levels in MDA-MB-
231, but they have not observed OPG in CM from MCF-7
cells [44].We detected intracytoplasmic expression of OPG,
RANKL and TRAIL in both cell lines, observing a de-
crease in the expression of OPG from the second day
(traditional culture conditions) in both cell lines. This
correlates with higher levels of OPG in the CM. Kapoor
et al. observed that the expression of OPG in MDA-
MB-231 cells is directly correlated with the colonization
and homing potential related to bone and not with me-
tastasis to other organs [56].
Based on these findings, it appears that OPG has a
multifactorial role in the development of osteolytic-type
bone metastasis, as in BC. An increase in the RANKL/
OPG ratio favors the formation of osteoclasts within the
bone microenvironment and is a bad prognostic factor in
BC patients [12]. In the present study, we were not able
to quantify the level of soluble RANKL in the CM of
BC cells. Nevertheless, we found that 100 % of BC cells
expressed membrane RANKL under both culture
Figure 5 Expression of membrane and cytoplasmic RANK (mRANK/cRANK), SDF-1 and CXCR4 in both BC cell lines. (A)
Immunocytochemistry staining for RANK, SDF-1 and CXCR4 in MDA-MB-231 and MCF-7 cells grown under arrest and post-stimulation culture
conditions (x 400 magnification). (B) The MDA-MB-231 and MCF-7 cell lines were incubated with irrelevant IgG1 and mouse Igs Abs as negative
isotype controls (x 400 magnification). Nuclei were counterstained with hematoxylin (purple).
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allowing these cells to proliferate, migrate and specific-
ally invade BM and bone. Brown et al. showed that
cells that metastasize to bone exhibit higher RANKL
expression than cells that metastasize to other organs
[57]. Therefore, BC cells could migrate to BM/bone
and promote the differentiation of preosteoclasts into
osteoclasts, thus further promoting the osteolytic
process that leads to the emergence of bone metastasis.
This suggests that the most important event for the
bone metastasis establishment is the increase in osteo-
clast formation and bone resorption processes that fi-
nally leads to the invasion and proliferation of BC cells
in bone.
We showed that 100 % of the cells from the MDA-
MB-231 and MCF-7 cell lines expressed RANK andSDF-1 under both culture conditions, despite showing
no detectable levels of this last factor released into the
CM. Moreover, analysis of CXCR4 expression exhibited
positive weak staining in 50 % of the cells from both BC
cell lines under both culture conditions. These results
suggest that cells expressing RANK and CXCR4 have
the ability to migrate to BM through the action of
RANKL and SDF-1 released by BM stromal cells, fibro-
blasts or osteoblasts [4,58-60].
Neville-Webbe et al. have shown that hormone inde-
pendent TRAILS’ sensitive BC cell lines cease being sen-
sitive in the presence of recombinant OPG, thereby
enhancing tumor cell survival [44]. In contrast, other
authors have reported that the anti-cancer efficacy of
TRAIL is retained in the presence of high, biologically
active concentrations of OPG in vivo [18]. These findings
Figure 6 Expression of TRAIL, TRAIL-R1, TRAIL-R2, TRAIL-R3 and TRAIL-R4 in both BC cell lines. (A) Immunocytochemistry staining for
TRAIL, TRAIL-R1, TRAIL-R2, TRAIL-R3 and TRAIL-R4 in the MDA-MB-231 and MCF-7 cell lines grown under arrest and post-stimulation culture
conditions (x 400 magnification). (B) The MDA-MB-231 and MCF-7 cell lines were incubated with anti-AE1AE3 (positive control) and with
irrelevant mouse Igs, goat IgG and IgG1 Abs as negative isotype controls (x 400 magnification). Nuclei were counterstained with hematoxylin
(purple).
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TRAIL and TRAIL-R in BC patients, particularly those
that are ER negative. Further investigation of the regula-
tion of TRAIL by OPG could aid in designing new thera-
peutic strategies, where the apoptotic action of TRAIL
could be increased in BC cells at the early stages of the
disease.
Regarding the release of TRAIL, the results of the
present study showed levels below the minimum level
detectable by ELISA in the CM from both tumor cell
lines. It is probable that in vitro, some of the multiple
factors needed for the release of TRAIL by BC cells are
absent, as this situation is very different from that
in vivo.
Yagita et al. have reported that the absence of total
TRAIL-R1 and R2 protein on the cell surface is suffi-
cient to account for the failure of apoptosis [21]. Thus,
evaluation of expression of these receptors could serve
as a potential predictive marker of TRAIL sensitivity in
BC cells. Moreover, positive TRAIL-R4 expression iscorrelated with tumoral grade in BC patients with inva-
sive ductal carcinoma [61], the expression of TRAIL-R is
associated with the resistance of MCF-7 cells to the ac-
tion of TRAIL and the expression of TRAIL-R3/R4
could compete with TRAIL-R1 and/or -R2 to binding
TRAIL blocking apoptosis signaling [62,63]. It appeared
to be important to assess TRAIL-R expression in the
MDA-MB-231 and MCF-7 cell lines to consolidate the
results under the two different culture conditions. Our
data showed that 100 % of the cells from both lines
expressed TRAIL-R1 and TRAIL-R4. However, we found
that only 30 to 55 % of these cells weakly express
TRAIL-R2 and TRAIL-R3, being stronger the TRAIL-R2
expression in MDA-MB-231 than in MCF-7 cell lines.
This study demonstrates the importance of obtaining
our own expression results of OPG, RANKL, RANK,
TRAIL, TRAIL-R (R1, R2, R3 and R4), SDF-1 and
CXCR4 in cultures from the human BC cell lines MDA-
MB-231 and MCF-7 in different culture conditions. Tak-
ing these findings together with those previously
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and mechanisms triggered prior to the appearance of
bone metastasis and during the interactions between
tumor cells, MSCs from BM and blood components in
greater detail. It will be of interest to study simultan-
eously these molecules in tumor biopsies as well as in
tumor epithelial cells isolated from BC patients. They
may be useful in identifying patients with bone risk, and
thus, they may improve decision related to the different
treatments to combat cancer progression.
Finally, despite the advances in knowledge about these
molecules, many questions remain unresolved, particu-
larly regarding the conflicting roles of OPG in bone me-
tastasis and the possible use of OPG as a potential
therapeutic factor for tumors that produce metastases in
BM and bone. In conclusion, MCF-7 and MDA-MB-231
cell lines not only released OPG but also expressed
RANKL, TRAIL and SDF-1. The majority of these cells
also expressed RANK, CXCR4 and TRAIL-R. Since
these ligands and their receptors are involved in the
regulation of breast tumor progression, the simultaneous
assessment of these molecules in tumor biopsies of BC
patients, particularly in the early clinical pathological
stage, could be useful in identifying patients with more
aggressive tumors that are also at risk of bone metasta-
sis, which may thus improve the available options for
therapeutic intervention.
Methods
Breast cancer cell lines
The MDA-MB-231 and MCF-7 lines were maintained in
DMEM/F12 with 100 IU/ml penicillin-G, 100 μg/ml
streptomycin sulfate, 25 μg/ml amphotericin B, 2 mM L-
glutamine (supplemented DMEM/F12) (Gibco/Life
Technologies, Grand Island, NY, USA) and 10 % fetal
bovine serum (FBS; Natocor, Argentina), complete
DMEM/F12, at 37 °C under 5 % CO2. In the case of the
MCF-7 line, 2 μg/ml of humanized porcine insulin (La-
boratories Beta, Argentina) was added. The medium was
changed every 3-4 days. The cells were used up to pas-
sage 4.
To better compare the expression of OPG, RANKL,
TRAIL, SDF-1 and their receptors (RANK, TRAIL-R1-4
and CXCR4), both BC cell lines were grown under two
culture conditions: A) traditional and B) adherence, ar-
rest and post-stimulation.
Traditional culture conditions (A)
The BC cell lines (18x103 or 50x103 cells/cm2) were cul-
tured in complete DMEM/F12 for 24, 48, 72 or 96 h.
Then, the CM were harvested from BC cell lines on days
1 to 4 (D1, D2, D3 and D4), centrifuged at 300 g for
15 min and stored at -20 ° C until use. This experiment
was repeated four times.Adherence, arrest and post-stimulation culture
conditions (B)
The BC cell lines (18x103 cells/cm2) were cultured in
complete DMEM/F12 without phenol red (D2906,
Sigma, St. Louis, MO, USA) for 24 h (adherence) and
then with supplemented DMEM/F12 without phenol
red, insulin and FBS for an additional 48 h (arrest). Fi-
nally, the cells were cultured with complete DMEM/F12
for 48 h (stimulus). The CM from the arrest and post-
stimulation culture conditions were harvested, centri-
fuged at 300 g for 15 min and stored at -20 ° C until use.
The experiment was repeated four times.
ELISA assays
The CM from both culture conditions (A and B) were
used to evaluate OPG, RANKL, TRAIL and SDF-1 levels
via ELISA methodology. Cells from both culture condi-
tions (A and B) were harvested using a solution of
trypsin-EDTA (0.05-0.02 % in PBS, Gibco) with the pur-
pose of evaluating the number of total cells/culture; the
levels of these factors were then expressed per 1x106
cells.
OPG, RANKL and SDF-1 levels were measured in the
CM using commercial ELISA kits (DY805, R&D, Minne-
apolis, MN, USA; RHF740CKC, Antigenix America,
Huntington Station, NY, USA; and DY350, R&D, respect-
ively). TRAIL was measured using an ELISA kit devel-
oped in our laboratory. This procedure was performed
according to the manufacturer’s recommendations for
human TRAIL/TNFSF10 (DY375, R&D) but using anti-
human TRAIL (MAB3751, R&D) as capture Ab; recom-
binant human TRAIL (rhTRAIL, 375-TL, R&D, at 31.25
to 2,000 pg/ml) to produce a standard curve; and anti-
human TRAIL (BAF375, R&D) as a detection Ab to-
gether with streptavidin-peroxidase (S5512, Sigma).
The enzyme activity was revealed using a 3,3′,5,5′-Tet-
ramethylbenzidine (TMB) substrate (Sigma), and it was
abolished using 1 N HCl (Merck). The absorbance was
read at 450 nm using a microplate reader set (BIO-RAD,
Hercules, CA, USA). Supplemented DMEM-F12 with
10 % FBS (D0) was used as a control, and its value was
eliminated as a test target. Samples were assayed in trip-
licate. The CM were assayed from four experiments run
under both culture conditions (A and B). The levels of
the OPG, RANKL, TRAIL and SDF-1 proteins from the
ELISA analyses were calculated in pg/ml/1x106 cells.
Immunofluorescence assays
The BC cells from both culture conditions (A and B)
were used to evaluate the expression of OPG, RANKL
and TRAIL via immunofluorescence. The experiment
was repeated four times for each culture condition.
BC cells (18x103 cells/well/130 μl) were grown on
multi-test slides (096041805, MP Biomedicals, Santa
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B). Then, the BC cells were washed with PBS and fixed
with 4 % paraformaldehyde for 30 min. After blocking in
PBS-1 % BSA, the cells were incubated with the follow-
ing primary human Abs: anti-OPG (AB21259, Chemi-
con, Billerica, MA, USA), anti-RANKL (MAB626, R&D)
and anti-TRAIL (MAB687, R&D). The presence of OPG
was visualized using FITC-labeled goat anti-rabbit IgG
(H+L) (FI-1000, Vector Lab), and the presence of
RANKL and TRAIL was visualized using Cy3-labeled
goat anti-mouse IgG (H+L) (111-165-146, Jackson). Fi-
nally, mounting media with DAPI was used to visualize
nuclei (Vectashield solution, H-1500, Vector Lab). Con-
focal microscopy analyses were performed using a Nikon
C1 laser-scanning confocal microscope (Plan Apo 40x/
0.95). The acquisition software used was MetaMorph
image analysis software.
BC cells were also incubated without primary Abs;
with irrelevant IgG1 [mouse IgG1 isotype (X0931, Dako,
Carpinteria, CA, USA)]; with normal mouse Igs (08-
6599, Zymed, San Francisco, CA, USA); or with normal
rabbit Igs (X0936, Dako) as a negative isotype control.
Each sample was assayed in quadruplicate.
Immunocytochemistry
The BC cells from both culture conditions (A and B)
were used to evaluate the expression of RANKL, RANK,
TRAIL-R1-4, SDF-1 and CXCR4 via immunocytochem-
istry assays. The experiment was repeated four times for
each culture condition.
BC cells (18x103 cells/well/130 μl) were fixed in 4 %
paraformaldehyde, except for cells that were used to
evaluate the expression of mRANKL and mRANK. After
blocking endogenous peroxidase activity and non-
specific sites (PBS-BSA 1 %), the BC cells were incubated
with the following primary human Abs: anti-RANKL
(AB1862, Chemicon), anti-RANK (MAB683, R&D), anti-
TRAIL-R1 (AF347, R&D), anti-TRAIL-R2 (MAB6311,
R&D), anti-TRAIL-R3 (MAB6301, R&D), anti-TRAIL-R4
(AF633, R&D), anti-SDF-1 (MAB350, R&D), anti-CXCR4
(MAB172, R&D) and anti-AE1AE3 as a positive control
(IR053, Dako). According to the manufacturer’s recom-
mendations, a peroxidase-based immunocytochemistry
staining method (K0690, Dako) was used for primary Ab
detection, and a 3,3′-diaminobenzidine tetrahydrochlor-
ide (DAB) substrate system (K3468, Dako) was used as
the chromogen.
Negative controls without primary Abs; with an irrele-
vant Ab as a negative isotype control [mouse IgG1 iso-
type (X0931, Dako)]; with normal mouse Igs (08-6599,
Zymed); with normal goat IgG (AB-108-C, R&D); or
with normal rabbit Igs (X0936, Dako) were used to assess
non-specific staining. Each sample was assayed in
quadruplicate.Statistical analysis
Data obtained from ELISA were expressed as X ± stand-
ard error (SE) pg/ml/1x106 cells. The statistical signifi-
cance of the differences in the measured values among
groups was evaluated by one-way analysis of variance
(ANOVA) followed by a Bonferroni post hoc test. For
individual comparisons, an independent unpaired t-test
with Welch's correction was used. A difference was con-
sidered statistically significant if p< 0.05.
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